Welcome to our dedicated page for JATT III Acquisition SEC filings (Ticker: JTTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on JATT III Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into JATT III Acquisition's regulatory disclosures and financial reporting.
JATT III Acquisition Corp (JTTT) received a Schedule 13D from its sponsor, JATT Ventures III L.P., and Chairman and CEO Dr. Someit Sidhu, reporting beneficial ownership of 1,959,000 ordinary shares, representing 22.1% of the company’s ordinary shares outstanding as of September 3, 2026.
The position consists of 1,725,000 Founder Shares acquired for $25,000 on June 9, 2026 (after a forfeiture of 431,250 shares) and 234,000 placement shares purchased for $2,340,000 in a private placement completed simultaneously with the August 27, 2026 IPO. The sponsor has sole voting and dispositive power over these shares, and Dr. Sidhu has voting and investment discretion through his control of the sponsor while disclaiming beneficial ownership beyond any pecuniary interest.
The filing describes agreements giving the sponsor registration rights and imposing a lock-up on the 234,000 placement shares until 30 days after completion of the company’s initial business combination, subject to certain exceptions. The sponsor has also agreed to vote its shares in favor of a proposed business combination and not to seek redemption of its shares. The reporting persons state they may buy or sell additional securities over time but currently have no specific plans for further transactions or corporate changes beyond executing the SPAC’s business combination strategy.
JATT III Acquisition Corp (JTTT) is the subject of a Schedule 13G reporting that RA Capital Healthcare Fund, L.P. directly holds 450,000 ordinary shares, with RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah reported as additional filing persons. These shares represent 5.1% of the ordinary shares outstanding, based on 8,859,000 ordinary shares outstanding as of August 27, 2026. The reporting persons have shared voting and shared dispositive power over 450,000 shares and report their holdings on a beneficial ownership basis under Section 13(d), while including customary disclaimers of beneficial ownership outside that context.
JATT III Acquisition Corp (JTTT) reported the closing of its initial public offering and related private placement, establishing its capital and trust structure as a newly formed SPAC. The company sold 6,900,000 ordinary shares at $10.00 per share on August 27, 2026, including 900,000 shares from the full exercise of the underwriter’s over-allotment option, generating $69,000,000 of gross proceeds.
Simultaneously, JATT Ventures III L.P. purchased 234,000 Private Placement Shares at $10.00 per share for $2,340,000. As of August 27, 2026, $69,000,000 (including $2,070,000 of deferred underwriting fees) was placed in a U.S. trust account for the benefit of public shareholders, while the balance sheet shows total assets of $70,797,500, cash outside the trust of $1,797,500, and working capital of $1,363,402. The company has 24 months from the IPO closing to complete an initial business combination, with 6,900,000 public shares classified as redeemable at $10.00 per share and 1,959,000 ordinary shares (including 1,725,000 Founder Shares and 234,000 Private Placement Shares) outstanding outside the redemption pool.
JATT III Acquisition Corp (JTTT) has a new significant shareholder group, as Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz report beneficial ownership of 400,000 ordinary shares of the company. Based on 7,725,000 ordinary shares outstanding as of August 25, 2026, this represents 5.2% of the class. The filing states that the filers have shared voting and dispositive power over all 400,000 shares and no sole voting or dispositive power. Commodore Capital LP is identified as investment manager to Commodore Capital Master LP, with Atkinson and Kramarz exercising investment discretion.
JATT III Acquisition Corp (JTTT) reports that Great Point Partners, LLC, together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, beneficially own 450,000 shares of its common stock, representing 5.83% of the class, based on 7,725,000 shares outstanding as of August 26, 2026.
The 450,000 shares are held through Biomedical Value Fund, L.P. (297,000 shares) and Biomedical Offshore Value Fund, Ltd. (153,000 shares). Great Point, Dr. Jay and Ms. Nordahl share voting and dispositive power over these shares and each disclaims beneficial ownership except to the extent of any pecuniary interest.
JATT III Acquisition Corp (JTTT) is reported to have a significant shareholder group led by Deep Track Capital and related entities, which collectively report beneficial ownership of 450,000 shares of Common Stock, representing 5.83% of the class as of September 2, 2026.
The reporting persons – Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin – state they have no sole voting or dispositive power over these shares, but share voting and dispositive power over all 450,000 shares. Percentages are calculated using 7,725,000 Common Stock outstanding as of August 26, 2026, as reported by JATT III Acquisition Corp.
JATT III Acquisition Corp (JTTT), a Cayman Islands SPAC, completed its initial public offering of 6,900,000 ordinary shares on August 27, 2026, including full exercise of the underwriters’ over-allotment option. Shares were sold at $10.00 each, generating $69,000,000 in gross proceeds and listing on NASDAQ under the ticker JTTT.
Simultaneously, the company sold 234,000 Private Placement Shares to its sponsor at $10.00 per share for $2,340,000. A total of $69,000,000 from the IPO and private placement was deposited into a U.S.-based trust account, to be released only upon a business combination, specified redemptions, or liquidation after 24 months from the IPO closing. In connection with the IPO, JATT III adopted an amended and restated charter and appointed four independent directors, who were also assigned to the audit, compensation, and nominating and corporate governance committees.
JATT III Acquisition Corp (JTTT) disclosed that its sponsor, JATT Ventures III L.P., purchased 234,000 Ordinary Shares at $10.00 per share on August 27, 2026, as private placement shares under a Private Placement Shares Purchase Agreement. Following this transaction, the sponsor holds 1,959,000 Ordinary Shares, over which Dr. Someit Sidhu has voting and investment discretion while disclaiming beneficial ownership except for any pecuniary interest.
JATT III Acquisition Corp (JTTT) is conducting an initial public offering of 6,000,000 ordinary shares at $10.00 per share, for gross proceeds of $60 million (up to 6,900,000 shares or $69 million if the over-allotment option is exercised in full). JATT III is a Cayman Islands blank check company (SPAC) formed to complete an initial business combination in healthcare, with emphasis on biotechnology and data-driven life sciences. At closing, $60–69 million will be placed in a U.S. trust account, to be used for a future business combination or redeemed to public shareholders. The company has a 24‑month “completion window”, with possible shareholder‑approved extensions, after which it will redeem 100% of public shares if no deal is completed. The structure is share‑only (no warrants), with public shareholders having redemption rights on a per‑share amount tied to trust funds. The sponsor holds 1,725,000 founder shares bought for $25,000 and will buy 225,000 private placement shares at $10.00, creating immediate dilution to public shareholders. Affiliates AI Biotechnology LLC and Vianti have each indicated non‑binding interest in up to $30 million and $15 million of additional shares in private placements at the time of the business combination.
JATT III Acquisition Corp (JTTT) reported an initial statement of beneficial ownership on Form 3 for director Christopher Staral. The filing does not list any share holdings or report any transactions in the company’s securities at this time.